Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03534986 |
Recruitment Status :
Completed
First Posted : May 23, 2018
Results First Posted : September 6, 2018
Last Update Posted : October 3, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cystic Fibrosis Bronchiectasis | Device: International Biophysics AffloVest Device: Hill-Rom The Vest Device: Respirtech inCourage Device: Electromed SmartVest | Not Applicable |
The study will be broken into three (3) arms:
- AffloVest® & The Vest®
- AffloVest® & inCourage®
- AffloVest® & SmartVest® Subjects will be randomly assigned to an arm. Within each arm, the order of products will be also randomized.
Baseline spirometry (Forced Expiratory Volume (FEV1), Forced Vital Capacity (FVC), Peak Expiratory Flow (PEF), Forced Expiratory Flow (FEF25-75%) and Tidal Volume (TV)) will be taken at the beginning, middle and end of each series of measurements with each subject, without any device on the subject.
A product (AffloVest or Compressor-based vest) will be placed onto subject and turned ON to the highest frequency and intensity settings. Then the subject will be given a certain period of time to adjust and spirometry measurements will then be repeated, then The product will be removed and the subject will be allowed a recovery period, then the other product will be placed on the subject, turned ON and spirometry measurements will repeated.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 32 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements |
Actual Study Start Date : | February 20, 2018 |
Actual Primary Completion Date : | March 16, 2018 |
Actual Study Completion Date : | March 16, 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: AffloVest The Vest Arm
Devices placed on highest intensity / highest frequency
|
Device: International Biophysics AffloVest
High-frequency chest wall oscillation vest Device: Hill-Rom The Vest High-frequency chest wall oscillation vest |
Experimental: AffloVest inCourage Arm
Devices placed on highest intensity / highest frequency
|
Device: International Biophysics AffloVest
High-frequency chest wall oscillation vest Device: Respirtech inCourage High-frequency chest wall oscillation vest |
Experimental: AffloVest SmartVest Arm
Devices placed on highest intensity / highest frequency
|
Device: International Biophysics AffloVest
High-frequency chest wall oscillation vest Device: Electromed SmartVest High-frequency chest wall oscillation vest |
- TV [ Time Frame: 30 minutes ]Tidal Volume, the lung volume representing the normal volume of air displaced between normal inhalation and exhalation when extra effort is not applied
- PEF [ Time Frame: 30 minutes ]Peak Expiratory Flow, a person's maximum speed of expiration
- FVC [ Time Frame: 30 minutes ]Forced Vital Capacity, the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible
- FEV1 [ Time Frame: 30 minutes ]Forced Expiratory Volume, the volume of air that can be forced out in one second after taking a deep breath
- FEF25-75% [ Time Frame: 30 minutes ]Forced Expiratory Flow (25-75%), the peak expiratory flow at 25 - 75% FVC

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy subject, ages 18 - 50
Exclusion Criteria:
- Non-ambulatory, diagnosed neuromuscular disorder, currently using any type of oscillation vest therapy, diagnosed co-morbid condition (i.e. lung cancer, other lung disorder or disease), currently enrolled in a medical research study, non-English speaking

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03534986
United States, Florida | |
PDS Research | |
Kissimmee, Florida, United States, 34741 |
Principal Investigator: | Thomas W O'Brien, MD | PDS Research |
Documents provided by International Biophysics Corporation:
Responsible Party: | International Biophysics Corporation |
ClinicalTrials.gov Identifier: | NCT03534986 |
Other Study ID Numbers: |
2017-02 |
First Posted: | May 23, 2018 Key Record Dates |
Results First Posted: | September 6, 2018 |
Last Update Posted: | October 3, 2018 |
Last Verified: | September 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
Cystic Fibrosis Bronchiectasis Pancreatic Diseases Digestive System Diseases Lung Diseases |
Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Bronchial Diseases |